GE HealthCare Technologies (NASDAQ:GEHC) Price Target Raised to $83.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price objective upped by BTIG Research from $75.00 to $83.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

GEHC has been the subject of a number of other research reports. Zacks Research upgraded GE HealthCare Technologies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of GE HealthCare Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, October 6th. Barclays upgraded shares of GE HealthCare Technologies to a “strong-buy” rating in a report on Wednesday, October 7th. BMO Capital Markets initiated coverage on GE HealthCare Technologies in a report on Wednesday, July 8th. They issued a “market perform” rating and a $70.00 price target for the company. Finally, Oppenheimer reiterated an “outperform” rating on shares of GE HealthCare Technologies in a research note on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.57.

GE HealthCare Technologies Stock Up 0.2%

GEHC opened at $76.57 on Wednesday. GE HealthCare Technologies has a 12 month low of $58.75 and a 12 month high of $89.77. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.30 and a quick ratio of 0.97. The business has a 50 day simple moving average of $68.45 and a 200-day simple moving average of $70.06. The stock has a market capitalization of $34.62 billion, a P/E ratio of 16.15, a P/E/G ratio of 1.99 and a beta of 0.73.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, October 28th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.14. GE HealthCare Technologies had a return on equity of 20.45% and a net margin of 9.96%. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the company posted $1.07 EPS. The business’s revenue was up 7.2% on a year-over-year basis. On average, equities analysts anticipate that GE HealthCare Technologies will post 5.01 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.2%. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.0350. The ex-dividend date of this dividend is Friday, October 23rd. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.67%.

Hedge Funds Weigh In On GE HealthCare Technologies

A number of large investors have recently modified their holdings of GEHC. Ascent Group LLC bought a new stake in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $453,000. Pzena Investment Management LLC acquired a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at $82,085,000. Rakuten Investment Management Inc. raised its stake in shares of GE HealthCare Technologies by 9.9% in the 3rd quarter. Rakuten Investment Management Inc. now owns 121,395 shares of the company’s stock valued at $8,068,000 after buying an additional 10,897 shares in the last quarter. Provenance Wealth Advisors LLC lifted its holdings in shares of GE HealthCare Technologies by 401.0% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 491 shares of the company’s stock worth $32,000 after acquiring an additional 393 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of GE HealthCare Technologies during the 3rd quarter worth about $21,123,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

More GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Strong Q3 results beat expectations. GE HealthCare reported $5.51 billion in revenue, above the $5.35 billion consensus estimate, while EPS of $1.34 exceeded expectations of $1.20. Revenue increased 7.2% year over year, helping drive the post-earnings gap higher. GE HealthCare Technologies Shares Gap Up After Strong Earnings
• Positive Sentiment: Management raised its full-year outlook. The company now expects approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and at least $1.6 billion in free cash flow. Organic growth of 6.2% and margin expansion in the quarter further strengthened the bullish case. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Analysts raised valuation targets. RBC increased its target from $80 to $90 and maintained an “outperform” rating. BNP Paribas lifted its target from $96 to $100, while Mizuho raised its target from $85 to $90. BTIG Research also forecast substantial potential appreciation. BNP Paribas Price Target Update
• Neutral Sentiment: JPMorgan raised its price target from $70 to $80 but kept a “neutral” rating, suggesting recognition of the earnings improvement while retaining a cautious stance on valuation. JPMorgan GE HealthCare Rating
• Neutral Sentiment: A value comparison with Haemonetics highlights GEHC’s investment appeal but does not introduce a material new catalyst for the stock. GEHC Versus HAE Value Comparison

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company’s portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.